Sandra Calvin, SVP, Chief Accounting Officer: Travere Therapeutics TVTX Planned sale · Filed 25/12/29

Trade details

Type: Planned sale notice
Stock: Travere Therapeutics TVTX
Person: Sandra CalvinSVP, Chief Accounting Officer
Planned sale date: 25/12/24
Filed: 25/12/29

More to sell after $2.5M in 3 months

Travere Therapeutics trades, last 26 weeks

What else happened in Travere Therapeutics around then

Filed or reported within 30 days of the trade day · 25/11/24~01/23

Sandra Calvin's recent trades

Sandra CalvinSVP, Chief Accounting Officer
Planned sale10b5-1 planTravere Therapeutics
Planned sale10b5-1 plan
Travere Therapeutics
TVTX
$353.6K
5,375 sh
$353.6K
Filed 09/15
Traded 09/15
Sandra CalvinSVP, Chief Accounting Officer
Sell10b5-1 planTravere Therapeutics
Sell10b5-1 plan
Travere Therapeutics
TVTX
$902.6K
21,977 sh
$902.6K
Filed 04/16
Traded 04/14
Sandra CalvinSVP, Chief Accounting Officer
Planned sale10b5-1 planTravere Therapeutics
Planned sale10b5-1 plan
Travere Therapeutics
TVTX
$902.6K
21,977 sh
$902.6K
Filed 04/14
Traded 04/14
Sandra CalvinSVP, Chief Accounting Officer
Planned saleTravere Therapeutics
Planned sale
Travere Therapeutics
TVTX
$139.2K
4,333 sh
$139.2K
Filed 02/03
Traded 02/03
Sandra CalvinSVP, Chief Accounting Officer
SellTravere Therapeutics
Sell
Travere Therapeutics
TVTX
$139.2K
4,333 sh
$139.2K
Filed 02/03
Traded 02/03

Sandra Calvin, CAO — plans to sell 7,402 sh of Travere Therapeutics TVTX · $296.1K · around 12/24 · 10b5-1 plan | Whalegun